Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | opioid receptor, mu 1 | Starlite/ChEMBL | References |
Homo sapiens | adenosine A3 receptor | Starlite/ChEMBL | References |
Homo sapiens | calcium channel, voltage-dependent, L type, alpha 1F subunit | Starlite/ChEMBL | References |
Homo sapiens | opioid receptor, kappa 1 | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1480 nM | Binding affinity against Na+ channels | ChEMBL. | 11585444 |
IC50 (binding) | = 3580 nM | Binding affinity against opioid receptor kappa 1 by using [3H]-U-69,593 as radioligand | ChEMBL. | 11585444 |
IC50 (binding) | = 3580 nM | Binding affinity against opioid receptor kappa 1 by using [3H]-U-69,593 as radioligand | ChEMBL. | 11585444 |
IC50 (binding) | = 3730 nM | Inhibition of human adenosine A3 receptor | ChEMBL. | 11585444 |
IC50 (binding) | = 3730 nM | Inhibition of human adenosine A3 receptor | ChEMBL. | 11585444 |
IC50 (binding) | = 3950 nM | Binding affinity against mu opiate receptor | ChEMBL. | 11585444 |
IC50 (binding) | = 3950 nM | Binding affinity against mu opiate receptor | ChEMBL. | 11585444 |
IC50 (binding) | = 4840 nM | Binding affinity against L-type calcium channel verapamil site | ChEMBL. | 11585444 |
IC50 (binding) | = 4840 nM | Binding affinity against L-type calcium channel verapamil site | ChEMBL. | 11585444 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.